A phase I dose-escalation/expansion study of fractionated-dose and multiple cycle anti-PSMA-targeted alpha emitter 225Ac-J591 in patients with prostate cancer.

Tagawa ST, Thomas C, Arham AB, Holmes A, Marulanda Corzo V, Okobi T, Vallabhajosula S, Avlonitis V, Huicochea Castellanos S, Nauseef JT, O'Dwyer E, Fatima M, Gregos P, Yuan S, Sternberg CN, Molina A, Nanus DM, Bander NH, Osborne J

Open source

DOI: 10.1158/1078-0432.ccr-26-0689
Published: 2026 Jul 22
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-26-0689,
  title = {A phase I dose-escalation/expansion study of fractionated-dose and multiple cycle anti-PSMA-targeted alpha emitter 225Ac-J591 in patients with prostate cancer.},
  author = {Tagawa ST and Thomas C and Arham AB and Holmes A and Marulanda Corzo V and Okobi T and Vallabhajosula S and Avlonitis V and Huicochea Castellanos S and Nauseef JT and O'Dwyer E and Fatima M and Gregos P and Yuan S and Sternberg CN and Molina A and Nanus DM and Bander NH and Osborne J},
  year = {2026},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-26-0689},
  url = {https://doi.org/10.1158/1078-0432.ccr-26-0689}
}

RIS

TY  - JOUR
TI  - A phase I dose-escalation/expansion study of fractionated-dose and multiple cycle anti-PSMA-targeted alpha emitter 225Ac-J591 in patients with prostate cancer.
AU  - Tagawa ST
AU  - Thomas C
AU  - Arham AB
AU  - Holmes A
AU  - Marulanda Corzo V
AU  - Okobi T
AU  - Vallabhajosula S
AU  - Avlonitis V
AU  - Huicochea Castellanos S
AU  - Nauseef JT
AU  - O'Dwyer E
AU  - Fatima M
AU  - Gregos P
AU  - Yuan S
AU  - Sternberg CN
AU  - Molina A
AU  - Nanus DM
AU  - Bander NH
AU  - Osborne J
PY  - 2026
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-26-0689
UR  - https://doi.org/10.1158/1078-0432.ccr-26-0689
ER  -

APA

ST, T., C, T., AB, A., A, H., V, M. C., T, O., S, V., V, A., S, H. C., JT, N., E, O., M, F., P, G., S, Y., CN, S., A, M., DM, N., NH, B., & J, O. (2026). A phase I dose-escalation/expansion study of fractionated-dose and multiple cycle anti-PSMA-targeted alpha emitter 225Ac-J591 in patients with prostate cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-26-0689

Source records

pubmed · retrieved 2026-09-27T12:01:07.070Z